The safety and efficacy of rimantadine for long-term prophylaxis of influenza A (H3N2) infection were evaluated among elderly residents in 10 nursing homes. Within each nursing home, participating residents were randomly assigned to receive placebo or rimantadine at 100 or 200 mg/day. Residents were evaluated daily for symptoms and significant health events as possible side effects, as well as for influenza-like illness. The study medications were administered to 328 residents for up to 8 weeks, with no statistically significant differences in the frequencies of gastrointestinal or central nervous system symptoms between the groups. However, residents in the active medication groups were more likely to withdraw from the study and to experience various health events including death; some but not all of these differences were statistically significant. Efficacy evaluations were carried out on the 68 vaccinated residents in the two nursing homes with demonstrated influenza virus activity. Rimantadine appeared to provide an additional protective effect beyond vaccination in reducing the risk of clinical and laboratory-confirmed influenza-like illness; however, the efficacy estimates were never statistically significant. The efficacies of the 100-and 200-mg/day dosages were generally similar. When data for the 100-and 200-mg/day dosage groups were combined and compared with data for the group receiving placebo, the efficacy of rimantadine in reducing the risk of clinical influenza-like illness was estimated to be 58 percent (P ‫؍‬ 0.079). The results suggest the relative safety and clinical efficacy of using rimantadine for influenza prophylaxis among vaccinated elderly individuals and support the recommendation for a dosage reduction to 100 mg/day in this population.
In spite of increasing vaccine use, type A (H3N2) influenza virus remains an important cause of severe morbidity and mortality in older individuals (6, 17, 19) . There is now considerable evidence of the protective effectiveness of vaccination in preventing hospitalizations in independently living elderly individuals, but institutional outbreaks of influenza still regularly occur, even in nursing homes with good vaccination rates in years in which the circulating virus resembles that in the vaccine (1, 3, 13, 22, 26) . Thus, the use of antiviral agents, first amantadine and now rimantadine, has been recommended to control outbreaks of type A influenza virus infection; the prophylactic use of antiviral agents has also been examined in nursing home settings (4, 10) .
The value of amantadine in the prevention and treatment of influenza virus infection has repeatedly been demonstrated, but its use has been constrained, mainly because of the issue of side effects (18, 20, 24) . In particular, use of amantadine in nursing homes was often accompanied by clusters of side effects, in part related to a lack of a reduction in the dose to reflect decreased renal function (16) . Rimantadine has been recognized as being as effective as amantadine and as producing fewer side effects in investigational studies (11) . When rimantadine was licensed for use in the United States in 1993, the dosage was designed to parallel that of amantadine. Thus, it was recommended that the drug be given at 200 mg daily, but with a reduction to 100 mg daily in elderly nursing home residents (8) . This recommendation was pragmatic since no efficacy data comparing the two dosages in institutions existed (5) . We decided to evaluate the long-term use of rimantadine for the prophylaxis of type A influenza virus at two dosages in nursing homes residents. The study was designed to examine differences in the frequency of side effects during long-term use and to determine prophylactic efficacy should there be sufficient type A influenza virus transmission.
MATERIALS AND METHODS
Data collection. Ten nursing homes in southern lower Michigan were recruited as study sites. Informed consent was obtained from the residents or their family members for the evaluation of the long-term safety and efficacy of rimantadine for prophylaxis of influenza virus infection. Residents with significant renal or hepatic disease were excluded from participation in the study. Demographic data along with information on chronic underlying conditions and influenza virus vaccination status were collected for all participants. The participating residents within each nursing home were randomly assigned to receive one of two dosages of active medication (100 or 200 mg of rimantadine per day) or placebo at a ratio of 2:2:1. Two doses were administered each day; for those in the 100-mg/day group, one dose was active drug and the other was placebo. Staff and residents were blinded to group assignment. Nursing home staff dispensed the medications to their participating residents once community surveillance indicated that type A influenza virus was circulating in the area. Compliance was monitored and side effect evaluations were recorded daily by nursing home staff. Staff were instructed to evaluate the participants by observing and questioning the residents on the incidence of symptoms representing potential side effects as deviations from the usual or typical state of health, since some participants routinely experienced the conditions in question. Data were collected on any significant health event, which was defined as a major change in health status whether or not the health event was included in the list of symptoms. Information on the date of and reasons for withdrawal from the study prior to study closure was collected. Data on reports of clinical influenza-like illness experienced by individual study participants were also collected. Influenza-like illness was defined as illness with fever plus cough or sore throat. Paired preseason (postvaccination, but before the outbreak) and postseason serum specimens were collected from participants to determine the occurrence of influenza virus infection serologically.
Influenza surveillance and determination of influenza virus infection. Influenza surveillance was carried out in the study area beginning in November 1993 in order to determine the timing and etiology of influenza virus circulation. Participating nursing homes and community-based medical practice sites reported weekly on the incidence of influenza-like illness at their sites. In addition, throat swabs from individuals with influenza-like illness were cultured to isolate influenza virus. Isolates were confirmed as type A influenza virus by an indirect fluorescent-antibody test and were subtyped in a hemagglutination inhibition assay (14) .
Serologic enzyme-linked immunosorbent assays were carried out on sera from participating residents who provided pre-and postseason specimens for laboratory confirmation of influenza virus infection (21) . Influenza virus infection was considered laboratory confirmed for those residents with a fourfold rise in antibody titer to a hemagglutinin-specific antigen for influenza virus A (H3N2) and/or for those residents whose throat swab collected during an influenza-like illness was positive for an influenza virus A (H3N2) isolate on culture. Analytic objectives and statistical analysis. Statistical analyses were carried out by using the SAS-PC and DEPID packages (12, 25) . Descriptive statistics were generated to characterize the study population by age, sex, underlying conditions, and influenza virus vaccination status. The three groups were compared on the basis of the likelihood of experiencing specific symptoms, the number of days that the person was symptomatic, and the rate of symptom development. Specific outcomes were compared by using chi-square and Fisher's exact tests, with risk ratios and confidence intervals calculated as appropriate. The outcomes used were: (i) an overall measure termed significant health events, which combined any medical or surgical condition considered significant by the nursing home staff, plus hospitalization and death; (ii) withdrawal from the study for any reason; (iii) withdrawal from the study attributed by nursing home staff to possible side effects; and (iv) death. In all cases the placebo group was used as the reference group.
The occurrence of influenza in the 10 nursing homes was defined on the basis of the generation of epidemic curves by using the weekly reports of influenza-like illness. Nursing homes experiencing outbreaks of influenza-like illness with laboratory-defined infection occurring in study participants were identified by using paired serum specimens. In the residents of these homes, three preventive efficacy outcomes were calculated: (i) influenza-like illness, also called clinical influenza, that is, illness meeting a case definition; (ii) laboratory-confirmed clinical influenza, that is, a subset of the above with either virus isolation or a rise in antibody titer, or both; or (iii) influenza virus infection, that is, a rise in antibody titer or virus isolation with or without clinical illness, or both (11, 20) . The estimates of efficacy were determined as 1 Ϫ risk ratio using the participants receiving placebo as the reference group.
RESULTS
Description of study population. Ten nursing homes with a total population of 1,182 residents agreed to participate in the study. Overall, 80 percent of the participating nursing homes' residents had been vaccinated against influenza virus during fall vaccination programs. The proportion of residents vaccinated varied significantly by nursing home and ranged from 64 to 96%. A total of 328 (28%) of the residents in the 10 nursing homes elected to participate in the study and were randomly assigned within each home to a prophylaxis or placebo group. The two groups receiving active medication were each twice as large as the placebo group. The mean age of the study population was 86 years, and 84% of the participants were women (Table 1) . In contrast to the residents in general, 93% of the participants had received influenza virus vaccine prior to the current influenza season. As expected, multiple chronic diseases, reported as present or absent, were common in this population. Neurologic disorders, heart disease, and hypertension were the chronic underlying conditions most frequently reported for the participants. There were no significant differences in mean age or frequency distributions for gender, proportion reporting influenza virus vaccination, or any of the measured underlying conditions by group.
Eight homes dispensed the study medication or placebo to the residents for a total of 8 weeks, one home dispensed the study medication or placebo for 7.5 weeks, and one home dispensed study medication or placebo for 6 weeks. Approximately 97% of the 328 participants complied with study drug or placebo administration by receiving at least 80% of the expected number of doses (91% received 90% of expected doses) while they were on the study drug or placebo regimen (compliance until withdrawal from the study or until study closure). Sixty-two (19%) residents withdrew from the study prior to the end of the data collection period.
Adverse event evaluations. Daily symptom evaluations were carried out by nursing home staff during study drug or placebo administration. In general, the potential side effects represented categories of gastrointestinal and central nervous system symptoms. Overall, 33% of study participants experienced at least one potential side effect (Table 2) . Participants in all three groups were equally likely to experience each of the specified symptoms. The most commonly reported symptom in all groups was confusion (10 to 14%). Nausea (8 to 11%) and loss of appetite (6 to 10%) were also frequently reported. Four (3%) participants in the 200-mg/day group and one (2%) participant in the placebo group experienced a seizure or clonic twitching during study drug or placebo administration. Three Other outcomes were examined as a means of increasing the ability to detect potential side effects in this chronically symptomatic population. The likelihood that at least one symptom was reported or that multiple days with symptoms was reported was not statistically significantly different between the groups (Table 3 ). In addition, those participants taking active medication were no more likely to report multiple different symptoms than those in the placebo group (data not shown). The amount of time on study medication or placebo until the first reported symptom did not differ significantly between assignment groups (Cox proportional hazards model; data not shown).
Differences by prophylaxis or placebo group in reporting a significant health event and other potentially major events were also evaluated (Table 3) . These outcomes are not mutually exclusive. Significant health events were a combined measure including conditions considered significant by nursing home staff, hospitalization, and death; among the events reported were myocardial infarctions, falls resulting in fractures, and hyperglycemic episodes. Participants in the 200-mg/day prophylaxis group were 2.3 times more likely to experience a significant health event than those in the placebo group (see Table 3 for confidence intervals; Fisher's exact test, P ϭ 0.031). Participants in the 100-mg/day group were 2.0 times more likely than those in the placebo group to experience a significant health event (Fisher's exact test, P ϭ 0.079).
Differences by group for study withdrawal are also presented in Table 3 . The reasons for study withdrawal included death, discharge, hospitalization, physician's request, refusal to continue participation, and a perceived side effect(s). Participants in the 200-mg/day group were 1.9 times more likely to withdraw from the study than individuals in the placebo group (Fisher's exact test, P ϭ 0.041). An increased risk of withdrawal from the study also tended to be observed when comparing the 100-mg/day group with the placebo group (Fisher's exact test, P ϭ 0.213). An increased risk of withdrawal from the study only on the basis of perceived side effects was demonstrated among participants in both groups receiving active medication, especially the 200-mg/day group, compared with the placebo group; however, these associations were not statistically significant.
Nineteen participants (6%) died during the study drug administration period; they resided in 9 of the 10 nursing homes. Eleven of these participants (8%) were assigned to the 100-mg/day prophylaxis group, 7 (5%) were assigned to the 200-mg/day prophylaxis group, and 1 (2%) was assigned to the placebo group. Death occurred throughout the study period: 5 deaths (26%) occurred in the first 2-week period, 6 (32%) occurred in the second 2 weeks, and 4 deaths each (21%) occurred in the third and last 2 week periods. For eight individuals, pneumonia was the single cause or the contributing cause (along with other events, such as cerebrovascular accidents) of death. The remaining causes of death were cardiac (five individuals, including three with myocardial infarction), cancer of various sites (three individuals), sepsis (two individuals), and multiple strokes (one individual). Cancer, although rare in this population (5%), was the only chronic underlying condition significantly related to a fatal outcome. In bivariate analyses, residents who died were more likely to be male, although not significantly, and they were significantly older than those participants who lived (mean age, 88.8 versus 86.1 years). No residents who reported chronic lung conditions died.
Prophylactic efficacy. Reported influenza-like illness and influenza virus isolation began in late November and continued through January. Influenza virus A (H3N2) was the only strain identified within the Michigan study area and was antigenically similar to the strain contained in the vaccine (9) . Influenza virus infection rates were evaluated among the study participants since they alone had contributed blood specimens. Paired pre-and postseason serum specimens were collected from 270 (82%) of the 328 residents on long-term prophylaxis. Twenty-one residents in four nursing homes had serologically confirmed influenza virus infection, and 19 were residents of two nursing homes that had peak periods of influenza-like illness activity documented by prospective weekly reporting.
Analyses to evaluate the efficacy of rimantadine in reducing the likelihood of influenza outcomes were carried out in the two nursing homes whose study participants had documented influenza virus infection. These analyses were limited to vaccinated individuals, since nearly all of the participants were in this category, and the analyses provided an estimate of the additive protective efficacy of rimantadine (Table 4 ). The administration of rimantadine at both dosages was associated with reductions in the likelihood of clinical influenza-like illness and laboratory-confirmed influenza virus infection when compared with administration of placebo (risk ratios, Ͻ1.0); however, in no case were the estimates statistically significant. Rimantadine was most efficacious at reducing the likelihood of clinical illness (57 to 60% efficacy) but was less effective in reducing the likelihood of laboratory-confirmed infection (6 to 50% efficacy). No additional benefit was demonstrated for the 200-mg/day dosage over the 100-mg/day dosage; most estimates produced nearly identical results, although sample size remains a limitation. In an additional analysis, the results of which are also presented in Table 4 , the efficacy of rimantadine in reducing the likelihood of clinical influenza-like illness was estimated for the groups receiving active prophylaxis combined versus the placebo group. In that analysis, efficacy was estimated to be 58% (P ϭ 0.079).
DISCUSSION
The present study was designed to address two issues: the long-term safety of rimantadine at two dosages among elderly nursing home residents and the efficacy of the medication in reducing the likelihood of clinical illness and laboratory-confirmed infection. While it could be expected that meaningful results would be generated on the first point, the second was dependent on the intensity of type A influenza virus transmission in the nursing homes under study. Vaccinated residents were more likely to participate in the study, and as a result, it was not possible to determine the efficacy of rimantadine in unvaccinated individuals. In any event, the major question concerning rimantadine was not whether efficacy in unvaccinated elderly individuals was different from that documented in young adults but, rather, whether rimantadine could produce protection in addition to that conferred by vaccination (11, 20) .
While influenza virus type A (H3N2) circulated within the study area, only two nursing homes participating in the study experienced significant influenza virus activity, reducing the numbers available for analysis. Efficacy estimates suggested that rimantadine provided additive protection among vaccinated individuals, especially against symptomatic illness. Failure to achieve statistical significance was related to the small number of nursing homes with influenza virus activity, which was probably a result of reasonably high vaccination rates (3). The 200-and 100-mg/day dosages produced very similar results. If there is an additional protective effect of the 200-mg/ day dosage, it must be very small. It would require a sample size of nearly 1,000 exposed individuals to demonstrate a 10% difference in efficacy between the two dosages. Less protection against overall infection than against symptomatic illness was detected, a well-known phenomenon demonstrated previously with both amantadine and rimantadine (11, 20) . When data for the two groups receiving active medication were pooled and evaluated versus data for the group receiving placebo, a nearly significant estimate of the efficacy of rimantadine in preventing clinical illness of 58% was demonstrated. This estimate is consistent with that from the single previous study of prophylaxis with rimantadine at 200 mg/day for protection against influenza-like illness in vaccinated individuals in nursing homes (10) . In both situations, it is unlikely that protection was adversely affected by the emergence of antiviral resistance, since the drug was used only as prophylaxis, and in the current study, only 28% of the nursing home residents were on the study drug (15) .
The study added a considerable body of information on the adverse reactions associated with the long-term use of rimantadine among elderly nursing home residents to that derived from previous smaller studies (23) . More than 300 individuals were followed for up to 8 weeks, and no statistically significant differences in the incidence of individual symptoms, including those previously associated with amantadine, were found (11) . This indicated the relative safety of rimantadine in this highrisk population, especially compared with that of amantadine (16) . Other outcomes were also examined to increase the sensitivity of detection of adverse events in a population with many underlying medical problems. Analyses did suggest greater frequencies of certain of these additional or combined outcomes. The differences might well represent rimantadinerelated adverse reactions, since they appeared more frequently among those receiving the 200-mg/day treatment dosage. An exception to this pattern was deaths among participants, which were more common among those receiving the 100-mg/day dosage. Death is a relatively frequent event in nursing home populations, and it is impossible to draw absolute conclusions about these deaths, given their distributions. Nine of 10 participating nursing homes reported fatal outcomes among participating residents. The recorded causes of death varied, and more than half involved an infectious process. They occurred throughout the study period, which would suggest that drug accumulation was not involved, although the fact that data on the pharmacokinetics of rimantadine when it is used in nursing home populations were limited is a problem. Even though the groups were randomly assigned by nursing home to receive prophylaxis or placebo, it is possible that the groups were not comparable on the basis of the extent of their underlying conditions, since data were collected on their presence or absence, and it was not possible to assess severity. It can be concluded from the present study that for longterm use, any difference, if one was present, in the efficacy of rimantadine between the 100-and 200-mg/day dosages would be small and probably not clinically relevant. Side effects appeared to be relatively uncommon in individuals receiving both dosages, but there was a suggestion of a greater frequency of adverse events in those receiving the 200-mg/day dosage; thus, the suggested reduction of the dosage to 100 mg/day among nursing home residents appears warranted (8) . Use of a 100-mg/day dosage in short-term outbreak-control situations is also reasonable, but data from pharmacokinetic studies might indicate the need for a loading dose in this situation (27) . In support of a previous study, long-term prophylaxis with rimantadine appears to provide protection to nursing home residents beyond that produced by vaccine, even in a year in which the infecting strain is similar to that in the vaccine (10) . It can be considered as prophylaxis for use in those years, and especially when the circulating type A influenza virus differs from that in the vaccine, as occurred in early 1993, when there were many nursing home outbreaks (7) . While long-term use to confer additional protection to vaccine remains judgmental, once transmission in a nursing home is recognized, current recommendations call for administration of an antiviral agent to all residents as a method of outbreak control (2, 8) .
